TheraRadar
← Back
Data updated: Mar 29, 2026

GLENMARK SPECLT

CardiovascularDermatologyInfectious Disease
Generics

GLENMARK SPECLT is a generic drug manufacturer focused on Cardiovascular, Dermatology, Infectious Disease. Key products include RYALTRIS.

2015
Since
23
Drugs
-
Trials
194
Approved (2yr)

Key Drugs

RYALTRIS
mometasone furoate
H1 receptor 1 indications · 2022
HAILEY 1.5/30
ethinyl estradiol
· 2018
HAILEY FE 1.5/30
ethinyl estradiol
· 2018

Top Drug Revenues Pro

Loading...

Revenue Over Time Pro

Loading...

Recent Activity

ACYCLOVIR 2026-01-22
Labeling
NORGESTIMATE AND ETHINYL ESTRADIOL 2026-01-07
Labeling
NITROGLYCERIN 2025-12-18
LINEZOLID 2025-12-08
CLOBETASOL PROPIONATE 2025-11-20
DEFERASIROX 2025-10-21
Labeling
DEFERASIROX 2025-10-21
Labeling
DEFERASIROX 2025-10-21
Labeling
SEC Filings Pro
Loading...

Therapeutic Areas

Score weights: Approved drugs ×3, Phase 3 ×2, Phase 2 ×1, Phase 1 ×0.5

Cardiovascular 33%
3 drugs
Dermatology 22%
2 drugs
Infectious Disease 22%
2 drugs
Oncology 11%
1 drugs
Gastroenterology 11%
1 drugs

Pipeline Forecast

Loading...

Upcoming Trial Milestones Pro

Loading...

Patent Cliff Pro

Loading...

Competitors by Therapeutic Area

Pfizer big-pharma
Oncology, Infectious Disease, Dermatology, Gastroenterology
Baxter specialty
Infectious Disease, Cardiovascular, Oncology, Dermatology
COSETTE other
Cardiovascular, Dermatology, Infectious Disease, Oncology
CASPER PHARMA LLC big-pharma
Infectious Disease, Oncology, Cardiovascular, Gastroenterology, Dermatology
FOUGERA PHARMS other
Dermatology, Infectious Disease, Oncology, Cardiovascular